- 全部删除
- 您的购物车当前为空

Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.
Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 μg | 待估 | 35日内发货 | |
50 μg | 待估 | 35日内发货 | |
100 μg | 待估 | 35日内发货 |
产品描述 | Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4. |
分子量 | 350.45 |
分子式 | C20H30O5 |
CAS No. | 110657-98-2 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
溶解度信息 | PBS (pH 7.2): 1 mg/mL (2.85 mM), Sonication is recommended. Ethanol: 50 mg/mL (142.67 mM), Sonication is recommended. DMF: 50 mg/mL (142.67 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
PBS (pH 7.2)/Ethanol/DMF
Ethanol/DMF
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容